Alnylam Pharmaceuticals, Inc. ALNY shares are trading higher by $41.00 or 54 percent at $116.04 in Wednesday's session.
The company announced positive Apollo Phase 3 results. The drug is used for the treatment of patients with hereditary ATTR amyloidosis with polyneuropathy.
See Also: Alnylam Pharmaceutical Surges After Rare Disease Drug Meets Key Endpoints
After a $20.00 higher open, it had a brief retreat to $96.34 before continuing its move higher. It has marched on to make new high after new high for the session.
At time of writing, $116.93 stood as the high for the day. That marks the highest level for the stock since August 6, 2015, when it peaked at $129.99, but weakened to end that session at $119.87. The following day, it fell to $106.19 following a worse than expected Q2 earnings report.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.